Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphomaChava Perry, Irit Avivi, Efrat Luttwak et al.|Blood Advances|2021Cited by 170
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort StudyRon Ram, Ronen Ben‐Ami, David Hagin et al.|Transplantation and Cellular Therapy|2021Cited by 164
Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating CellsMichael Timaner, Yuval Shaked, Nitzan Letko-Khait et al.|Cancer Research|2018Cited by 103
Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemiaYishai Ofran, Avraham Frisch, Shimrit Ringelstein‐Harlev et al.|Leukemia|2019Cited by 69
Novel Approaches to Acute Myeloid Leukemia ImmunotherapyOfrat Beyar‐Katz, Saar Gill|Clinical Cancer Research|2018Cited by 63